GSK’s Focuses Bioelectronics Quest On Blocking Single-Organ Neural Signals
This article was originally published in The Pink Sheet Daily
In the final part of its three-prong effort to advance the nascent field of bioelectronics, GSK will award a $1 million prize to researchers who are first able to solve the single-organ nerve interface challenge. Previously, the pharma launched its bioelectronics R&D unit and Action Potential Venture Capital to spur progress in this area.
You may also be interested in...
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.